76X0 のPS 比率は同業他社と比較してどうか。

76X0は、同業他社の平均 ( { 4.8 x) と比較したPrice-To-Sales比率 ( 4.3 x) に基づいて高価です。

76X0'のPS レシオは、European Life Sciences 業界の他社と比較してどうか。

76X0は、 European Life Sciences業界平均 (4.5x) (4.8 x) と比較すると、 Price-To-Sales比率 ( 4.5 x) に基づくと高価です。

76X0'のPS レシオとフェアPS レシオを比較すると？これは、会社の予想利益成長率、利益率、その他のリスク要因を考慮した予想PS レシオです。

76X0は、推定される公正Price-To-Sales比率 ( 4.8 x) と比較して、そのPrice-To-Sales比率 ( 1.1 x) に基づくと高価です。

76X0 、その将来キャッシュフローを見たときの公正価格はいくらになるだろうか？この見積もりには、割引キャッシュフローモデルを使用します。

評価分析のための76X0の公正価値を計算するためのデータが不十分です。

アナリストの12ヶ月の予想と、コンセンサス目標株価に対する統計的信頼性は？

目標価格は現在の株価より20 % 以上高いですが、アナリストは統計的に信頼できる範囲内で合意していません。

Standard BioTools ( ) - 株価, ニュースと分析DB:76X0

76X0 株式概要

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. 詳細

76X0 ファンダメンタル分析
スノーフレーク・スコア
評価	0/6
将来の成長	1/6
過去の実績	0/6
財務の健全性	6/6
配当金	0/6

報酬

収益は年間16.43%増加すると予測されています

リスク分析

過去3か月間の株価の変動は非常に激しい

現在は利益が出ておらず、今後3年間で利益が出る見込みはない

Standard BioTools Inc. 競合他社

Evotec

XTRA:EVT

€1.9b

Gerresheimer

XTRA:GXI

€2.5b

SCHOTT Pharma KGaA

XTRA:1SXP

€4.0b

Sartorius

XTRA:SRT3

€13.4b

価格と性能

の歴代最高値、変動、値下がりまとめStandard BioTools
過去の株価
現在の株価	US$1.93
52週高値	US$3.28
52週安値	US$1.59
ベータ	1.64
11ヶ月の変化	-14.60%
3ヶ月変化	12.21%
1年変化	-29.56%
33年間の変化	n/a
5年間の変化	n/a
IPOからの変化	-77.16%

Recent updates

株主還元

	76X0	DE Life Sciences	DE 市場
7D	-13.1%	1.1%	-0.6%
1Y	-29.6%	10.6%	9.6%

業界別リターン: 76X0過去 1 年間で10.6 % の収益を上げたGerman Life Sciences業界を下回りました。

リターン対市場: 76X0は、過去 1 年間で9.6 % のリターンを上げたGerman市場を下回りました。

価格変動

Is 76X0's price volatile compared to industry and market?
76X0 volatility
76X0 Average Weekly Movement	12.0%
Life Sciences Industry Average Movement	5.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

安定した株価: 76X0の株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: 76X0の weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1999	451	Adam Taich	www.somalogic.com

Standard BioTools Inc. 基礎のまとめ

Standard BioTools の収益と売上を時価総額と比較するとどうか。
76X0 基礎統計学
時価総額	€361.71m
収益（TTM）	-€119.03m
売上高(TTM)	€74.61m

4.8x

P/Sレシオ

-3.0x

PER（株価収益率

76X0 は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
76X0 損益計算書（TTM）
収益	US$81.72m
売上原価	US$97.89m
売上総利益	-US$16.16m
その他の費用	US$114.22m
収益	-US$130.38m

直近の収益報告

Sep 30, 2023

次回決算日

該当なし

一株当たり利益（EPS）	-0.69
グロス・マージン	-19.78%
純利益率	-159.54%
有利子負債／自己資本比率	0%

76X0 の長期的なパフォーマンスは？

過去の実績と比較を見る

76X0 株式概要

報酬

リスク分析

Standard BioTools Inc. 競合他社

XTRA:EVT

€1.9b

XTRA:GXI

€2.5b

XTRA:1SXP

€4.0b

XTRA:SRT3

€13.4b

価格と性能

最新ニュース

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Recent updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Madryn Asset Management, LP Issues Presentation to SomaLogic Shareholders

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

Somalogic, Inc. Provides Revenue Guidance for the Full Year 2023

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.18 loss in 3Q 2022)

Somalogic Announces New Somascan® 11K Platform

SomaLogic, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

SomaLogic, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Somalogic, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.022 loss in 1Q 2022)

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

Less than half of directors are independent

Full year 2022 earnings released: US$0.59 loss per share (vs US$0.64 loss in FY 2021)

SomaLogic, Inc. Provides Revenue Guidance for Full Year 2022

SomaLogic, Inc. Announces the Full-Scale Global Launch of the SomaLogic Certified Site Program

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.30 loss in 3Q 2021)

High number of new and inexperienced directors

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2022

SomaLogic, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SomaLogic, Inc. Announces the Appointment of Troy Cox as Executive Chairman of the Board of Directors

Melody Harris to Leave SomaLogic, Inc. as President and Chief Operating Officer, Effective August 31, 2022

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.12 loss in 2Q 2021)

SomaLogic Provides Revenue Guidance for the Full Year 2022

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SomaLogic, Inc. Announces Resignation of Stephen Quake from the Board of Directors, Effective July 17, 2022

First quarter 2022 earnings released: US$0.022 loss per share (vs US$0.13 loss in 1Q 2021)

SomaLogic, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

SomaLogic, Inc., Annual General Meeting, Jun 06, 2022

SomaLogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings released: US$0.64 loss per share (vs US$0.81 loss in FY 2020)

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

SomaLogic, Inc. to Report Q4, 2021 Results on Mar 29, 2022

Now 23% undervalued after recent price drop

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

SomaLogic Announces That the Company Will Begin Assaying Samples from the Multi-Ethnic Study of Atherosclerosis (Mesa) Study Beginning in the First Quarter of 2022

Oncohost Ltd. Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy

SomaLogic, Inc. Revises Revenue Guidance for the Year Ended December 31, 2021

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.55 loss per share

Director recently bought €136k worth of stock

No independent directors

株主還元

価格変動

会社概要

Standard BioTools Inc. 基礎のまとめ

4.8x

-3.0x

収益と収入